Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients

(4:50)

Mosunetuzumab induces deep and durable remissions in 3L R/R follicular lymphoma

(4:46)

Mosunetuzumab induces CR in B-NHL R/R to CAR-T

(9:26)

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma

(9:36)

Subcutaneous mosunetuzumab in R/R B-cell lymphoma

(1:20)

Mosunetuzumab for chemotherapy-intolerant DLBCL

(2:52)

Efficacy and safety of mosunetuzumab monotherapy for R/R follicular lymphoma

(1:12)

Mosunetuzumab: next-generation antibody for follicular lymphoma

(7:9)

The Inflammasome

(11:58)

Dr. Joe Schwarcz discusses monoclonal antibody research

(3:55)

Inflammasomes at the Crossroads of Basic Science and Therapeutic Intervention

(1:8:22)

Understanding Diffuse Large B-Cell Lymphoma with Jennifer Amengual, MD

(10:9)

Episode 27: What to Know About Neuroendocrine Tumor Liver Metastases

(46:13)

Inflammasome activation

(4:59)

Immunology: innate immunity, Neutrophil Homing

(9:20)

Glofitamab in R/R DLBCL: updated safety and efficacy data

(5:30)

Mechanistic model-informed discovery \u0026 development of bispecific antibodies for immuno-oncology

(55:53)

Introducing the inflammasome

(1:)

Mosunetuzumab individualized risk mitigation approach for NHL

(2:42)

Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in R/R FL

(1:55)

Epcoritamab versus mosunetuzumab in patients with R/R FL: findings of a MAIC

(2:16)

Mosunetuzumab in B-NHL R/R to CAR-T

(1:26)

Mosunetuzumab monotherapy in R/R FL

(2:4)

Stephen Schuster: Mosunetuzumab Leads to Durable Complete Remissions in Non-Hodgkin Lymphoma

(4:13)

Advantages of bispecific antibodies for lymphoma: mosunetuzumab, epcoritamab \u0026 glofitamab

(1:31)

Mosunetuzumab in B-NHL R/R to CAR-T

(1:45)

The value of mosunetuzumab in R/R FL

(1:46)

Mosunetuzumab in untreated FL and MZL: a response-adapted trial

(55)

Efficacy of mosunetuzumab monotherapy in elderly/unfit patients with previously untreated DLBCL

(3:43)

Pivotal findings from a Phase I/II trial of mosunetuzumab monotherapy for R/R follicular lymphoma

(5:25)